Back

Pimavanserin for the Treatment of Alzheimer's Disease Psychosis: An Evaluation of the Clinical Importance of Efficacy Results

2022-08-12 pharmacology and therapeutics Title + abstract only
View on medRxiv
Show abstract

Alzheimers disease psychosis (ADP) is a common and serious condition with substantial unmet need for safe and effective treatments. Pimavanserin is approved in the US to treat Parkinsons disease hallucinations and delusions. This post-hoc analysis of randomized, double-blind, placebo-controlled, phase 2 trial of nursing-home-residents with ADP evaluated the efficacy of pimavanserin by improvements (least squares mean change) in the Neuropsychiatric Inventory-Nursing Home Version Psychosis Score ...

Predicted journal destinations

1
Clinical Pharmacology & Therapeutics
19 training papers
Top 0.3% 12.0%
2
Frontiers in Pharmacology
27 training papers
#1 12.0%
3
British Journal of Clinical Pharmacology
21 training papers
Top 0.2% 7.9%
4
PLOS ONE
1737 training papers
Top 71% 6.5%
5
Scientific Reports
701 training papers
Top 44% 6.1%
6
Neuropsychopharmacology
29 training papers
Top 1% 2.8%
7
Brain, Behavior, and Immunity
35 training papers
Top 0.9% 2.2%
8
Brain Communications
79 training papers
Top 7% 2.0%
9
Brain
69 training papers
Top 6% 2.0%
10
The British Journal of Psychiatry
21 training papers
Top 0.8% 2.0%
11
Frontiers in Psychiatry
56 training papers
Top 6% 2.0%
12
PLOS Medicine
95 training papers
Top 8% 1.6%
13
Annals of Neurology
43 training papers
Top 5% 1.6%
14
Translational Psychiatry
94 training papers
Top 7% 1.6%
15
Age and Ageing
27 training papers
Top 1% 1.6%
16
Journal of Alzheimer’s Disease
23 training papers
Top 2% 1.4%
17
Alzheimer's & Dementia
84 training papers
Top 7% 1.4%
18
NeuroImage: Clinical
77 training papers
Top 9% 1.4%
19
Molecular Psychiatry
84 training papers
Top 9% 1.0%
20
JAMA Network Open
125 training papers
Top 23% 1.0%
21
eLife
262 training papers
Top 45% 1.0%
22
Nature Communications
483 training papers
Top 54% 1.0%
23
Antimicrobial Agents and Chemotherapy
17 training papers
Top 0.6% 1.0%
24
Trials
24 training papers
Top 2% 1.0%
25
GeroScience
22 training papers
Top 2% 1.0%
26
BMJ Open
553 training papers
Top 67% 0.7%
27
JMIRx Med
29 training papers
Top 4% 0.7%
28
Journal of Affective Disorders
72 training papers
Top 7% 0.7%